Nonpersistence
- Nonpersistence的基本解释
-
-
[医]无坚持力
- 更多网络例句与Nonpersistence相关的网络例句 [注：此内容来源于网络，仅供参考]
-
Increased seerity of heart failure or increased number of concomitant medications did not worsen persistence, but nonpersistence identified a high-risk population of patients who required special attention.
心衰恶化或治疗药物数量的增长并不使持续治疗的比例减少，但在高危病人中没有持续治疗值得特别关注。
-
Increased seerity of heart failure or increased number of concomitant medications did not worsen persistence, but nonpersistence identified a high-risk population of patients who required special attention.
关注早期开始治疗，合适的剂量，以及坚持用法很可能会带来远期的获益。
-
Fie years after initiation of treatment, 79% patients were still on renin-angiotensin inhibitors, 65% on -blockers, 56% on spironolactone, and 83% on statins. Notably, multiple drug treatment and increased seerity of heart failure was associated with persistence of treatment. Nonpersistence with renin-angiotensin inhibitors,-blockers, and statins was associated with increased mortality with hazard ratios for death of 1.37 (95% CI, 1.31 to 1.42), 1.25 (95% CI, 1.19 to 1.32), 1.88 (95% CI, 1.67 to 2.12), respectiely.
开始治疗5年后，有79％病人继续使用肾素血管紧张素抑制剂，65％用阻滞剂，56％用安体舒通，83％使用他汀类，值得注意的是，联合用药和心衰的加重同坚持治疗相关，无法坚持使用肾素血管紧张素抑制剂，阻滞剂，安体舒通，他汀类药物的病人同增加的死亡率相关，其死亡危险比分别为1.37 (95%可信区间， 1.31 － 1.42)， 1.25 (95%可信区间， 1.19 － 1.32)， 1.88 (95%可信区间， 1.67 － 2.12)，。
-
Nonpersistence with renin-angiotensin inhibitors,-blockers, and statins was associated with increased mortality with hazard ratios for death of 1.37 (95% CI, 1.31 to 1.42), 1.25 (95% CI, 1.19 to 1.32), 1.88 (95% CI, 1.67 to 2.12), respectiely.
不能持续应用肾素－血管紧张素抑制剂，阻滞剂和他汀与死亡率增加相关死亡的危险系数分别为1.37 (95% CI， 1.31 to 1.42)， 1.25 (95% CI， 1.19 to 1.32)， 1.88 (95% CI， 1.67 to 2.12)。